Bio

Leveraging decades of experience, Robert Freedman provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in going public transactions, including IPOs, de-SPACs, reverse mergers and direct listings, and in follow-on offerings and private placements of equity and debt securities. Rob previously co-chaired Fenwick’s Public Company and Capital Markets practice.